710 related articles for article (PubMed ID: 27385177)
21. When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions.
Patilea-Vrana GI; Unadkat JD
Drug Metab Dispos; 2018 Nov; 46(11):1487-1496. PubMed ID: 30115647
[TBL] [Abstract][Full Text] [Related]
22. Efflux transport of nicotine, cotinine and trans-3'-hydroxycotinine glucuronides by human hepatic transporters.
Järvinen E; Sjöstedt N; Koenderink JB; Kidron H; Finel M
Basic Clin Pharmacol Toxicol; 2019 Dec; 125(6):490-498. PubMed ID: 31237077
[TBL] [Abstract][Full Text] [Related]
23. Drug transport proteins in the liver.
Faber KN; Müller M; Jansen PL
Adv Drug Deliv Rev; 2003 Jan; 55(1):107-24. PubMed ID: 12535576
[TBL] [Abstract][Full Text] [Related]
24. Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics.
Zamek-Gliszczynski MJ; Day JS; Hillgren KM; Phillips DL
Drug Metab Dispos; 2011 Oct; 39(10):1794-800. PubMed ID: 21708882
[TBL] [Abstract][Full Text] [Related]
25. Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro.
Zhang Y; Han YH; Putluru SP; Matta MK; Kole P; Mandlekar S; Furlong MT; Liu T; Iyer RA; Marathe P; Yang Z; Lai Y; Rodrigues AD
Drug Metab Dispos; 2016 Mar; 44(3):320-8. PubMed ID: 26714763
[TBL] [Abstract][Full Text] [Related]
26. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
27. Transporter-Mediated Drug-Drug Interactions and Their Significance.
Liu X
Adv Exp Med Biol; 2019; 1141():241-291. PubMed ID: 31571167
[TBL] [Abstract][Full Text] [Related]
28. Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.
Järvinen E; Troberg J; Kidron H; Finel M
Mol Pharm; 2017 Oct; 14(10):3299-3311. PubMed ID: 28850245
[TBL] [Abstract][Full Text] [Related]
29. Interaction of Drug or Food with Drug Transporters in Intestine and Liver.
Nakanishi T; Tamai I
Curr Drug Metab; 2015; 16(9):753-64. PubMed ID: 26630906
[TBL] [Abstract][Full Text] [Related]
30. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
[TBL] [Abstract][Full Text] [Related]
31. Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.
Ferslew BC; Köck K; Bridges AS; Brouwer KL
Drug Metab Dispos; 2014 Sep; 42(9):1567-74. PubMed ID: 24958844
[TBL] [Abstract][Full Text] [Related]
32. Role of Hepatic Drug Transporters in Drug Development.
Liu H; Sahi J
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S11-22. PubMed ID: 27385168
[TBL] [Abstract][Full Text] [Related]
33. Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies.
Ghibellini G; Leslie EM; Pollack GM; Brouwer KL
Pharm Res; 2008 Aug; 25(8):1851-60. PubMed ID: 18509604
[TBL] [Abstract][Full Text] [Related]
34. Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System.
El-Kattan AF; Varma MVS
Drug Metab Dispos; 2018 May; 46(5):729-739. PubMed ID: 29496721
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
[TBL] [Abstract][Full Text] [Related]
36. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C; Fromm MF; König J
Drug Metab Rev; 2010 Aug; 42(3):380-401. PubMed ID: 20100011
[TBL] [Abstract][Full Text] [Related]
37. Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition.
Ulloa JL; Stahl S; Yates J; Woodhouse N; Kenna JG; Jones HB; Waterton JC; Hockings PD
NMR Biomed; 2013 Oct; 26(10):1258-70. PubMed ID: 23564602
[TBL] [Abstract][Full Text] [Related]
38. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
Kunze A; Huwyler J; Camenisch G; Poller B
Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
[TBL] [Abstract][Full Text] [Related]
39. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
Feng B; Varma MV
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
[TBL] [Abstract][Full Text] [Related]
40. Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling.
Bosgra S; van de Steeg E; Vlaming ML; Verhoeckx KC; Huisman MT; Verwei M; Wortelboer HM
Eur J Pharm Sci; 2014 Dec; 65():156-66. PubMed ID: 25261337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
